AMTD completes the HK IPO of Shanghai Henlius Biotech, Inc.
On September 25th, 2019, Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK), a leading biopharmaceutical company in China, was successfully listed on the main board of Hong Kong Stock Exchange, becoming the largest offering size biotech IPO issuer so far in 2019 and the Chinese biopharmaceutical company with the greatest market capitalization at the time of IPO. Meanwhile, Henlius is also the 9th innovative biotech company being successfully listed on HKEX, after Hong Kong Exchange revised its listing rules in April 2018. AMTD acted as the Lead Underwriter, Joint Bookrunner and Joint Lead Manager of the Henlius IPO, assisting the company to land in the international capital market successfully. The transaction marks the 4th IPO of leading biotech and innovative medical companies completed by AMTD, after IntelliCentrics (6819.HK), Aptorum (NASDAQ: APM) and IVD Medical (1931.HK), and it is also the 14th IPO issuance completed by AMTD in 2019. AMTD has assisted Fosun International (656.HK) with the issuance of multiple USD bonds and the HK IPO of its subsidiary, Fosun Tourism Group (1992.HK) since 2017. AMTD once again collaborated with a Fosun Group company in the international capital market, demonstrating the deepening cooperation between AMTD and Fosun Group in the international capital market.
Henlius raised over US$409 million (pre-shoe), and US$471 million (assuming the green shoe option is fully exercised), becoming the largest offering size biotech IPO issuer so far in 2019 and the Chinese biopharmaceutical company with the greatest market capitalization at the time of IPO. The IPO was highly coveted by domestic and foreign investors, and the International Offer Shares were oversubscribed. Cornerstone investors accounted for approximately 34.19% of the pre-shoe offering size, including Cayman Henlius, AI-Rayyan Holding LLC (a wholly-owned subsidiary of Qatar Investment Authority), AVICT Global Holdings Limited (a subsidiary of Shenzhen Putai Finance Service Co. Ltd.), and Zhejiang Staidson Investment Co. Ltd.
As the Lead Underwriter, Joint Bookrunner and Joint Lead Manager, AMTD has leveraged its resourceful investor coverage network and strong comprehensive service capabilities and fully explored the needs of investors. It ranked second among the underwriting syndicate by the demand introduced in the International Offering tranche, contribution and book building performance. AMTD successfully assisted Henlius to be the largest offering size biotech IPO issuer so far in 2019 and the Chinese biopharmaceutical company with the greatest market capitalization at the time of IPO.
Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative drugs for patients worldwide. Its product range covers diseases including tumor and autoimmune diseases. Henlius is the first biopharmaceutical company to receive NDA approval from the NMPA for a monoclonal antibody biosimilar in accordance with the Biosimilar Guidelines, the prevailing PRC regulation on biosimilar evaluation and marketing approval, and the first to commercially launch a biosimilar product in China. Since its inception in 2010, Henlius had built an integrated and innovative global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes. Discovering new ways to improve and extend patients’ lives by driving access to high-quality biologics worldwide, Henlius is committed to biosimilar, innovative monoclonal antibody (mAb) products and immuno-oncology combination therapies with proprietary anti-PD-1/PD-L1 mAbs as backbone on an integrated platform covering the entire product lifecycle from R&D, commercial-scale production to commercialization. Until now, in addition to one product launched commercially, two products under New Drug Application (NDA) review and one product under Marketing Authorization Application (MAA) review, Henlius has conducted over 20 clinical studies for 14 products and 6 combination therapies worldwide. HLX01 (汉利康®, rituximab injection), the Company’s first product, has been granted approval by the NMPA as the first approved biosimilar in China. Moreover, HLX03 (adalimumab injection) and HLX02 (trastuzumab for injection) have their NDAs under priority review by the NMPA. HLX02 is the first China-manufactured biosimilar to enter a global multi-center phase 3 clinical trial in China, Poland, Ukraine and the Philippines. In June 2019, MAA for HLX02 was accepted to review by EMA. In addition, the Company has carried out a number of immuno-oncology combination therapies with HLX10 and its proprietary products including HLX04 (bevacizumab biosimilar), HLX07 (anti-EGFR monoclonal antibody), other monoclonal antibodies and chemotherapy, while conducting multiple clinical studies worldwide.
As a comprehensive financial institution rooted in Hong Kong, backed by China and covering the globe, AMTD has always been committed to providing clients with open-end, innovative, diversified and professional financial services and helping more and more companies from different regions and diversified industries to expand business coverage, implement strategic goals and achieve global layout. AMTD has long been dedicated to investment and deployment in the field of biotech and innovative medical services. Besides Henlius, AMTD has successfully assisted the listings of IntelliCentrics (6819.HK), innovative medical technology platform; IVD Medical (1931.HK), China's leading in vitro diagnostic (IVD) market distributor; and Aptorum Group (NASDAQ: APM), Hong Kong's leading medical innovation and biopharmaceutical company on the Hong Kong Stock Exchange and the US Nasdaq Stock Market over the past twelve months.